Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 24;28(9):1379–1388.e7. doi: 10.1016/j.chembiol.2021.05.019

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Elsevier Ltd.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Affinity-matured nanobodies possess a combination of CDRs from the two lead clones

(A) Affinity maturation of lead nanobodies KA1 and KC3 via error-prone PCR results in nanobody variants that possess one CDR from each lead nanobody (CDR2 [red] from KA1 and CDR3 [blue] from KC3) in addition to one CDR (CDR1 [green]) that differs by only a single mutation.

(B) Nanobody sequences (Kabat numbering) for the three affinity-matured variants. Residues that are different from KA1.ep1 are indicated with an amino acid letter.